TRIgnite- 1Study, Phase 1, First-in-Human Study of ISB 2001: A BCMAxCD38xCD3-Targeting Trispecific Antibody for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)—Dose Escalation (DE) Results — Hang Quach (2025) | RDL Network
TRIgnite- 1Study, Phase 1, First-in-Human Study of ISB 2001: A BCMAxCD38xCD3-Targeting Trispecific Antibody for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)—Dose Escalation (DE) Results
Eben I. Lichtman, Amit Khot, Bradley Augustson, David Levitz, Hanlon Sia, Nicole Wong Doo, Michaela Liedtke, Camille Martinet, Vinu Menon, Andrew Garton, Harjeet Sembhi, Maria Pihlgren, Cyril Konto, Beata Holkova, Lida Pacaud, Hang Quach
Andrew Garton, Vinu Menon, Hang Quach, Amit Khot, Bradley Augustson, Hanlon Sia, Nicole Wong Doo, David Levitz, Eben I. Lichtman, Michaela Liedtke, Camille Martinet, Beata Holkova, Harjeet Sembhi, Lida Pacaud, Sunitha Gn, Maria Pihlgren, Mario Perro, Cyril Konto
Shaji Kumar, Magdalini Migkou, Manisha Bhutani, Andrew Spencer, Sikander Ailawadhi, Anna Kalff, Farzana L. Walcott, Nabendu Pore, D. Gibson, Fujun Wang, Lily Cheng, Ioannis Kagiampakis, Marna Williams, Krista Kinneer, Yu Jiang, Jeffrey A. Zonder, Jeremy T. Larsen, Shreerang Sirdesai, Andrew J. Yee, Meletios A Dimopoulos
Meletios A Dimopoulos, Magdalini Migkou, Manisha Bhutani, Sikander Ailawadhi, Anna Kalff, Farzana L. Walcott, Nabendu Pore, Miranda Brown, Fujun Wang, Lily Cheng, Ioannis Kagiampakis, Marna Williams, Krista Kinneer, Yuling Wu, Yu Jiang, Robert Kubiak, Jeffrey A. Zonder, Jeremy T. Larsen, Shreerang Sirdesai, Andrew J. Yee, Shaji Kumar
Discussion(0)
No comments yet. Be the first to comment.